Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate, which is trastuzumab linked to the DM1 and was approved by the FDA for ERBB2-positive breast cancer patients with residual invasion. This evidence concerns the gene ERBB2 and breast carcinoma.